中国医药(600056) - 2021 Q1 - 季度财报

Financial Performance - Operating revenue for the period was CNY 8,571,905,223.52, representing a year-on-year increase of 14.52%[4] - Net profit attributable to shareholders was CNY 212,945,092.47, a decrease of 19.35% compared to the same period last year[3] - Basic earnings per share were CNY 0.1993, a decrease of 19.34% compared to CNY 0.2471 in the same period last year[3] - The company reported a net profit of ¥6,536,312,481.29, an increase from ¥6,323,367,388.82, reflecting a growth of 3.37%[14] - Net profit for Q1 2021 was approximately ¥268.92 million, a decrease of 13.4% from ¥310.45 million in Q1 2020[18] - The company achieved a total comprehensive income of approximately ¥268.92 million for Q1 2021, compared to ¥310.45 million in Q1 2020[18] Cash Flow - The net cash flow from operating activities was CNY -588,255,884.34, an improvement from CNY -1,272,710,926.51 in the previous year[3] - The total cash received from operating activities was 30,810,000 CNY, a decrease of 32,321,000 CNY or 51.20% year-on-year, primarily due to a significant recovery of deposits in the previous period[9] - The cash inflow from operating activities was approximately ¥7.97 billion, a decrease of 18.4% compared to ¥9.78 billion in Q1 2020[21] - The company reported a cash outflow from operating activities totaling approximately ¥8.56 billion, compared to ¥11.06 billion in Q1 2020[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 32,906,783,339.07, a decrease of 0.86% compared to the end of the previous year[3] - The total liabilities decreased from 17,132,562,947.88 CNY to 16,446,049,307.92 CNY, indicating a reduction in financial obligations[13] - Total liabilities reached approximately 9.39 billion, with current liabilities at 8.99 billion and non-current liabilities at 396.79 million[29] - Current assets totaled ¥9,557,658,836.67, down 6.93% from ¥10,270,382,237.60 as of December 31, 2020[15] Shareholder Information - The total number of shareholders at the end of the reporting period was 83,136[7] - The largest shareholder, China General Technology (Group) Holding Co., Ltd., held 41.27% of the shares[7] Expenses - Research and development expenses totaled 1,035,000 CNY, a decrease of 501,000 CNY or 32.65% year-on-year, mainly due to reduced expenditures in the research phase[9] - Financial expenses amounted to 3,721,000 CNY, down 2,525,000 CNY or 40.43% compared to the previous year, primarily due to reduced borrowing and corresponding interest expenses[9] - Research and development expenses for Q1 2021 were approximately ¥10.35 million, a decrease of 32.5% from ¥15.36 million in Q1 2020[17] Government Support - The company received government subsidies amounting to CNY 17,224,289.05, which are closely related to its normal business operations[5] - Other income increased by 490,000 CNY to 1,722,000 CNY, a growth of 39.75%, mainly due to increased government subsidies received during the period[9]